Rituximab can be used in the treatment of rheumatoid arthritis, but in our country currently belongs to the super-indication for the use of drugs, the use of the method should be strictly in accordance with the doctor’s instructions.
Rituximab is a monoclonal antibody targeting CD20, which can inhibit autoimmune reactions by binding to B lymphocytes. The drug is mainly used for the treatment of non-Hodgkin’s lymphoma and other hematologic tumors in China. Although the drug in foreign countries in the treatment of rheumatoid arthritis in have more rich experience, but the drug is currently in China’s indications do not include rheumatoid arthritis.
In the super indications of rituximab, it can be used for rheumatoid arthritis treatment by intravenous infusion. According to foreign clinical trials, common adverse reactions include respiratory and urinary tract infections and infusion-related reactions. Rituximab is contraindicated in people who are allergic to any of the components contained in the drug, in people with severe heart failure, in people with severe active infections, or in people with severely impaired immune response.
Rheumatoid arthritis patients who need to use rituximab treatment, need to be used under the guidance of a doctor, do not blindly self-medication.